<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006421</url>
  </required_header>
  <id_info>
    <org_study_id>GB-NBVUB</org_study_id>
    <nct_id>NCT01006421</nct_id>
  </id_info>
  <brief_title>Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo</brief_title>
  <acronym>GB</acronym>
  <official_title>Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant
      psychosocial impact on patients and society. Different treatment modalities with variable
      success rates are available.

      Phototherapy is among the successful treatments but gives modest results. Some reports
      documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB)
      might give better results than using either one alone. This might improve repigmentation as
      well as patients' quality-of-life. (QOL).

      This will be a prospective double-blind randomized controlled clinical trial.
      One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per
      group).

      One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly.

      The other group will receive placebo tablets( identical in size, shape and color) to GB twice
      daily with NBUVB twice weekly.

      Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for
      both groups.

      Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than
      placebo or not.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Repigmentation (more than 50% from baseline) as the primary outcome</measure>
    <time_frame>3,6 and 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life - as secondary outcome .</measure>
    <time_frame>3,6 and 9 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Vitiligo</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GINGKO BILOBA</intervention_name>
    <description>MEMOREX 60 MG BID</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        DERMATOLOGY CLINIC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo.

          -  Body surface area (BSA) involvement â‰¥ 3%.

        Exclusion Criteria:

          -  Unable to consent

          -  Any topical, systemic or phototherapy for Vitiligo in the previous 2 months.

          -  Pregnancy, breast feeding.

          -  Liver or kidney disease.

          -  Epilepsy

          -  Bleeding disorder or anticoagulant treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KHALID M ALGHAMDI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>KSU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KHALID M ALGHAMDI, MD</last_name>
    <phone>4690815</phone>
    <email>kmgderm@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <state>Central</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KHALID M ALGHAMDI, MD</last_name>
      <phone>4690815</phone>
      <email>kmgderm@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>KHALID M ALGHAMDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2009</study_first_submitted>
  <study_first_submitted_qc>November 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <last_update_submitted>November 4, 2009</last_update_submitted>
  <last_update_submitted_qc>November 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>DR KHALID ALGHAMDI</name_title>
    <organization>KSU</organization>
  </responsible_party>
  <keyword>phototherapy</keyword>
  <keyword>Gingko biloba</keyword>
  <keyword>repigmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

